Literature DB >> 11343997

Extended sector biopsy for detection of carcinoma of the prostate.

P M.A. M D 1, T H. Niemann, R R. Bahnson.   

Abstract

Purpose: To determine whether an extended sector biopsy of the prostate will increase the detection of prostate cancer, without causing an increase in morbidity. Materials and
Methods: A total of 74 men with a mean age of 62.3 years (46-98 years) who either had an elevated PSA or an abnormal digital rectal exam underwent a transrectal ultrasound guided needle biopsy. Beginning on 7/1/98, an extended sector biopsy technique was performed on 74 patients by one urologist (RRB). Each transrectal ultrasound guided needle biopsy included 12 total cores (normal sextant biopsy, 2 in each peripheral zone, and 2 in the transition zone). We retrospectively reviewed the biopsy results for the location of cancer. PSA data and morbidity of the procedures were reviewed.
Results: Of 74 total patients, 40 (54.1%) were positive for adenocarcinoma of the prostate. There were 10 positive results detected only in the additional zones. If one looks at the total number of cancers detected (40), then 10/40 (25%) of the cancers detected were found in the additional regions only or in 13.5% of all patients biopsied. Of the 10 patients with sector only prostate cancer, 8 were detected in the peripheral zone, 1 in the transition zone and 1 in both zones. All 10 patients had a Gleason pattern score 3+3=6 or 4+3=7. There were no atypical or PIN cores found in the sector zones only. PSA ranged from 1.2-142 (median 6.0 ng/ml). The median PSA was 6.2 ng/ml in all patients found to have cancer, and 6.0 ng/ml in the cancers detected only in the additional zones. There was 1 (1.4%) complication of urinary retention and fever.
Conclusion: Our study suggests that an extensive sector biopsy may increase the detection of prostate cancer by 13.5% over a routine sextant biopsy, without demonstrable serious morbidity.

Entities:  

Year:  2001        PMID: 11343997     DOI: 10.1016/s1078-1439(00)00111-3

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  6 in total

1.  Skin biopsy rates and incidence of melanoma: population based ecological study.

Authors:  H Gilbert Welch; Steven Woloshin; Lisa M Schwartz
Journal:  BMJ       Date:  2005-08-04

2.  D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging.

Authors:  Ardeshir R Rastinehad; Angelo A Baccala; Paul H Chung; Juan M Proano; Jochen Kruecker; Sheng Xu; Julia K Locklin; Baris Turkbey; Joanna Shih; Gennady Bratslavsky; W Marston Linehan; Neil D Glossop; Pingkun Yan; Samuel Kadoury; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  J Urol       Date:  2011-01-15       Impact factor: 7.450

3.  Quantifying the role of PSA screening in the US prostate cancer mortality decline.

Authors:  Ruth Etzioni; Alex Tsodikov; Angela Mariotto; Aniko Szabo; Seth Falcon; Jake Wegelin; Dante DiTommaso; Kent Karnofski; Roman Gulati; David F Penson; Eric Feuer
Journal:  Cancer Causes Control       Date:  2007-11-20       Impact factor: 2.506

4.  Rising PSA in patients with minor LUTS without evidence of prostatic carcinoma: a missing link?

Authors:  Koenraad van Renterghem; Gommert Van Koeveringe; Philip Van Kerrebroeck
Journal:  Int Urol Nephrol       Date:  2007-06-30       Impact factor: 2.370

Review 5.  A new algorithm in patients with elevated and/or rising prostate-specific antigen level, minor lower urinary tract symptoms, and negative multisite prostate biopsies.

Authors:  Koenraad van Renterghem; Gommert Van Koeveringe; Ruth Achten; Philip van Kerrebroeck
Journal:  Int Urol Nephrol       Date:  2009-06-03       Impact factor: 2.370

Review 6.  Diagnostic accuracy of prostate needle biopsy.

Authors:  Timothy Donahue; Judd Moul
Journal:  Curr Urol Rep       Date:  2002-06       Impact factor: 2.862

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.